Changeflow GovPing Healthcare & Life Sciences Nucleic Acid Storage and Transport at Ambient T...
Routine Notice Added Final

Nucleic Acid Storage and Transport at Ambient Temperatures

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

Board of Regents, The University of Texas System, published patent application US20260108624A1 (filed September 25, 2023) for liquid and substantially solid film compositions enabling long-term storage, transport, and delivery of nucleic acids and other molecules without ultralow temperature requirements. Inventors Trang Doan and Maria Croyle claim compositions that maintain nucleic acid integrity at ambient temperatures, potentially eliminating cold-chain storage needs for biological materials.

“Aspects of the present disclosure are directed to liquid and substantially solid film compositions for storage, transport, and administration of agents, including nucleic acids, without the use of ultralow temperatures.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.

What changed

The USPTO published patent application US20260108624A1 for The University of Texas System, disclosing compositions and methods for storing, transporting, and delivering nucleic acids and other therapeutic molecules at ambient temperatures without ultralow freezing. The application covers both liquid and substantially solid film formulations, and injectable or oral compositions comprising the disclosed nucleic acid formulations. No regulatory obligations are imposed by this publication.

Entities in the pharmaceutical, biotechnology, and research sectors should monitor this patent landscape for potential licensing opportunities or freedom-to-operate considerations. The disclosed compositions may compete with existing cold-chain dependent nucleic acid delivery systems, including certain mRNA vaccine and gene therapy platforms requiring frozen storage.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

METHODS AND COMPOSITIONS FOR TRANSPORT, STORAGE, AND DELIVERY OF NUCLEIC ACIDS AND OTHER MOLECULES

Application US20260108624A1 Kind: A1 Apr 23, 2026

Assignee

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventors

Trang DOAN, Maria CROYLE

Abstract

Aspects of the present disclosure are directed to liquid and substantially solid film compositions for storage, transport, and administration of agents, including nucleic acids, without the use of ultralow temperatures. Provided are compositions capable of long-term storage of nucleic acids at ambient temperatures. Also disclosed are injectable or oral compositions comprising nucleic acids, as well as methods for formulation and administration of such compositions.

CPC Classifications

A61K 48/0041 A61K 47/16 A61K 47/22 A61K 47/26 A61K 47/32 C12Q 1/6806

Filing Date

2023-09-25

Application No.

19116798

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260108624A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent application filing IP licensing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Biotechnology Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!